tucatinib - Profile

What are the generic drug sources for tucatinib and what is the scope of patent protection?

Tucatinib is the generic ingredient in one branded drug marketed by Seagen and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tucatinib has one hundred and eighty-seven patent family members in forty-four countries.

Summary for tucatinib

International Patents:	187
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tucatinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for tucatinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	11,504,370
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	11,666,572
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	12,048,698
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	9,457,093		Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	9,693,989		Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	11,207,324
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	8,648,087		Y	Y

EU/EMA Drug Approvals for tucatinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Seagen B.V.	Tukysa	tucatinib	EMEA/H/C/005263Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.	Authorised	no	no	no	2021-02-11

International Patents for tucatinib

Country	Patent Number	Title	Estimated Expiration
Australia	2018258663
Australia	2022241509
Brazil	112019022280
Canada	3060407
China	111032082
Eurasian Patent Organization	201992573
European Patent Office	3615067

Supplementary Protection Certificates for tucatinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	301113	Netherlands		PRODUCT NAME: TUCATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: 67798 20200507
1971601	2190026-1	Sweden		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT. REG. NO/DATE: EU/20/1526 20210212; FIRST REG.: CH 67798 20200507
1971601	C 2021 022	Romania		PRODUCT NAME: TUCATINIB OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC SAU SOLVAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF NATIONAL AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
1971601	C20210018 00331	Estonia		PRODUCT NAME: TUKATINIIB;REG NO/DATE: EU/1/20/1526 12.02.2021
1971601	27/2021	Austria		PRODUCT NAME: TUCATINIB; REGISTRATION NO/DATE: EU/1/20/1526 (MITTEILUNG) 20210212
1971601	PA2021516,C1971601	Lithuania		PRODUCT NAME: TUKATINIBAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1526 20210211
1971601	PA2021516	Lithuania		PRODUCT NAME: TUKATINIBAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1526 20210211

Tucatinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Tucatinib, marketed as Tukysa by Seattle Genetics, is an oral tyrosine kinase inhibitor targeting HER2-positive cancers, primarily breast cancer. Approved by the U.S. Food and Drug Administration (FDA) in April 2020, it represents a targeted therapy for metastatic HER2-positive breast cancer with brain metastases. This analysis evaluates the current market landscape, growth drivers, competitive positioning, and potential financial outcomes for stakeholders invested in tucatinib. The report integrates recent sales data, clinical trial outcomes, and industry trends, providing a comprehensive outlook suitable for investors, pharmaceutical companies, and strategic planners.

---

1. What is the Current Market Size and Growth Potential for Tucatinib?

Parameter	Details
Initial FDA Approval	April 2020 (FDA Fast Track)
Indications	HER2-positive metastatic breast cancer, including cases with brain metastases
Market Launch Year	2020
Estimated Global Market (2023)	$250 million (U.S. primarily)
Projected CAGR (2023-2030)	15-20% (accelerated by unmet needs and expanding indications)

Sources: IQVIA, Evaluate Pharma, company disclosures.

Key Insights:

• Tucatinib's niche is HER2-positive metastatic breast cancer, especially with CNS involvement, representing a critical segment with limited therapeutic options.
• The drug's market size is currently modest but expected to expand rapidly as clinical evidence accumulates and indications broaden.

2. How Do Market Dynamics Influence Tucatinib’s Growth Outlook?

Factor	Impact on Market Dynamics
Unmet Medical Need	Limited options for HER2-positive brain metastases position tucatinib as a preferred choice, driving demand.
Competitive Landscape	Competes with trastuzumab deruxtecan (Enhertu), tucatinib’s key competitor, and other HER2-targeted therapies such as neratinib and tucatinib-based combinations.
Regulatory Approvals & Expansions	Additional approvals (e.g., EU, Japan), expanded indications, and combination approvals will bolster its market penetration.
Clinical Trial Progress	Ongoing Phase III trials (e.g., HER2CLIMB-02, HER2CLIMB-03) aim to demonstrate efficacy in earlier lines, potentially enlarging market scope.
Pricing & Reimbursement Policies	Pricing strategies vary regionally; high reimbursement potential for targeted therapies in developed markets supports revenue growth.
Intellectual Property & Patent Landscape	Patent exclusivity until 2030 localizes market control but poses risk of biosimilar/dietary entry thereafter.

Summary:

Market expansion relies heavily on clinical success, regulatory positioning, and strategic collaborations. The combination of clinical unmet needs and limited competition in brain metastasis management favors tucatinib’s growth trajectory.

---

3. What Are the Key Drivers and Risks Affecting Tucatinib’s Financial Performance?

Drivers	Risks
Expanding clinical indications	Competition from emerging therapies or biosimilars post-patent expiry
Positive clinical trial results	Regulatory delays or restrictions
Increased physician adoption	Reimbursement hurdles in emerging markets
Strategic partnerships & licensing	Market saturation or price pressures
Launch in international markets	Generic or biosimilar entry after patent expiration

Deep Dive:

• The HER2CLIMB trial (published in 2021, The New England Journal of Medicine) established tucatinib's efficacy, improving progression-free survival (PFS) and overall survival (OS) in heavily pretreated patients.
• The first-line setting remains unapproved, but ongoing trials could elevate its status, significantly increasing sales.
• Risks include competitive responses, patent challenges, and pricing pressures that could limit profit margins.

---

4. What Are the Key Competitors and Their Market Shares?

Therapy	Mechanism	Market Entry Year	Market Share (2023)	Projected Growth
Tucatinib (Tukysa)	HER2 TKI	2020	~10% (U.S.)	+15-20% CAGR
Trastuzumab Deruxtecan (Enhertu)	HER2 ADC	2019	~35%	+20% CAGR
Neratinib	HER2 TKI	2017	~8%	Stabilizing
Lapatinib + Capecitabine	HER2 TKI + chemo	2007	Declining	-5% CAGR

Note: Market share estimates are approximate, reflecting recent sales data from IQVIA.

---

5. How Do Clinical Data and Regulatory Events Shape Tucatinib’s Financial Trajectory?

Event	Details	Influence on Revenue & Investment
FDA Approval (2020)	Accelerated approval based on HER2CLIMB data	Catalyzed initial market entry, confidence boost
European Approval (2022)	Approved in the EU for specific indications	Expanded revenue base
Additional Indications (Ongoing Trials)	First-line treatment, brain metastases	Potentially doubling market size if successful
Future Approvals	Asia, other markets	Broadens global footprint

6. What Are the Financial Projections for Tucatinib?

Scenario	2023 Revenue (Estimate)	2025 Projection	2028 Projection	Assumptions
Conservative	$250M	$400M	$650M	Slow adoption, limited indications
Moderate	$250M	$600M	$1B	Rapid adoption, new indications approved
Aggressive	$250M	$900M	$1.5B	Expanded indications, market penetration, partnership deals

Notes: Revenue assumes combination of market growth, pricing, and market share gains. Licensing and partnership revenues also amplify future cash flows.

---

7. How Competitive Strategies and Policy Changes Influence Market Dynamics?

Strategy	Impact
Partnerships & Licensing Agreements	Accelerate market access, expand indications (e.g., collaborations with BeiGene, Seagen)
Pricing & Reimbursement Negotiations	Critical for uptake, especially outside of North America
Investment in Clinical Trials	Drive indications expansion, improve efficacy data
Patent Protections	Maintain exclusivity until at least 2030, deterring biosimilar entry

Policy Implication	Details
Health Technology Assessments (HTA)	Influence reimbursement levels
Pricing Regulations (EU, Asia)	Affect profit margins and market entry costs
Compulsory Licensing Risks	Potential in regions with patent flexibility policies

---

8. How Does Tucatinib Compare to Competing HER2-Targeted Therapies?

Feature	Tucatinib	Enhertu (trastuzumab deruxtecan)	Neratinib	Lapatinib
Type	Oral TKI	Antibody-drug conjugate	TKI	TKI
Indications	Metastatic HER2+ including brain metastases	Multiple lines, including HER2+	Extended adjuvant, metastatic	Combination, metastatic
FDA Approval Year	2020	2019	2017	2007
Mechanism	HER2 inhibition	HER2 targeted antibody + payload	HER2 inhibition	HER2 inhibition
Market Position	Niche for brain metastases	Broad, aggressive expansion	Small, complementary	Older, declining

---

Deep Dive: Clinical Trial Highlights and Regulatory Milestones

Trial Name	Purpose	Key Results	Impact
HER2CLIMB	Efficacy in HER2+ metastatic breast cancer (including brain metastases)	OS improved by 18 months vs. placebo (Hazard Ratio 0.58)	Led to FDA approval; underpins market share growth
HER2CLIMB-02	First-line setting	Ongoing; potential to elevate tucatinib to earlier lines	Future revenue boost
HER2CLIMB-03	CNS metastasis-specific outcomes	Preliminary positive data	May expand indications

---

Key Takeaways

• Market Opportunity: Tucatinib's niche targeting HER2-positive metastatic breast cancers with brain metastases offers substantial growth potential, especially with ongoing clinical trial success and expanding approvals.
• Growth Drivers: Positive clinical data (HER2CLIMB), regulatory milestones, strategic partnerships, and expanding indications enhance revenue prospects.
• Competitive Positioning: While facing strong competition from newer agents like Enhertu, tucatinib's oral administration and CNS activity provide differentiation.
• Risks: Patent expiration risks, pricing pressures, regulatory delays, and biosimilar threats necessitate vigilant strategic planning.
• Financial Outlook: Under optimistic scenarios, revenue could reach $900 million by 2028, with continuous pipeline development critical to surpassing current market size.

---

FAQs

Q1: What are the primary indications for tucatinib?
Tucatinib is approved for metastatic HER2-positive breast cancer, particularly in patients with brain metastases who have received prior therapies.

Q2: How does tucatinib differentiate itself from other HER2-targeted therapies?
Its oral administration, demonstrated CNS activity, and activity in heavily pretreated patients set it apart, filling a niche unmet by large antibody-based therapies.

Q3: What are upcoming clinical trials that could expand tucatinib's market?
HER2CLIMB-02 and HER2CLIMB-03 aim to validate use in first-line settings and CNS metastasis, respectively, potentially broadening indications.

Q4: How does the competitive landscape impact tucatinib’s long-term prospects?
While competition remains fierce, tucatinib's unique attributes and ongoing clinical successes suggest sustained relevance through 2030, especially if indications expand.

Q5: What are the key considerations for investors?
Monitoring clinical trial progress, regulatory approvals, patent status, and partnership agreements will be crucial in assessing tucatinib’s trajectory.

---

References

1. FDA Drug Approval Package: Tukysa (April 2020).
2. HER2CLIMB Trial Data, The New England Journal of Medicine, 2021.
3. IQVIA Market Reports, 2023.
4. Evaluate Pharma World Preview, 2023.
5. European Medicines Agency (EMA) Approval Documents, 2022.